SCROLL NEWS / DISCOVERY
Search headlines
Find the stories shaping the conversation.
Results for " Biotech " 100 found 🔀 AI-powered Shuffle
Sign in to save shuffle history.
Xeris adds longtime biotech exec to its board
The move to bring Menassie Taddese on comes amid reports that the Chicago-based rare disease and endocrinology drug company is being considered for acquisition.
Xtalks Announces its Life Science Webinar Calendar for November 2026
Stay on top of current hot topics through free webinars presented by leading experts in the pharma, biotech, medical device and healthcare industries. Access to all webinars is free, so be sure to register today to save your place! Participate in the discussion and stay relevant in your field!
Firm Advises Oxford Science Enterprises on IP Matters Related Sensible’s $47 Million Financing
On October 6, 2026, Sensible Biotechnologies (Sensible), a biotechnology company developing a first-of-its-kind platform for naturally modified mRNA medicines, announced that it has secured $47…
New Orleans-based biotech company lured to SC as first for MUSC lab
The company name was deliberately chosen from West African lore: Obatala, the god who shaped the human body. And the New Orleans biotech firm is determined to see that their human-based research lab m...
Santa Cruz County business: Biotech company acquired; Joby lands more Air Force funding
Global immunology company Argenx is acquiring Unnatural Products, a Santa Cruz-headquartered company focused on developing new treatments for certain types of rare cancers and diseases, in a deal that could be worth upward of $1 billion, Jessica M. Pasko reports in her weekly roundup of local business. She's also got news on funding for Joby Aviation from the Air Force's innovation arm, the launch of this year's Lookout List and plenty more.
Science 37 Named 2026 “BioTechnology Innovation of the Year” for its Direct-to-Patient Clinical Trial Delivery Model
[Announcement text for desktop] [Shorter announcement text for mobile] Learn more
TriGemX Bio and TCGX Acquisition Corp. Announce Business Combination Agreement to Create Publicly Listed Company to Develop Elismetrep, A Potential First-in-Class Treatment for Migraine
TriGemX Bio, a biotechnology company focused on developing elismetrep, a potential first-in-class treatment for migraine, and TCGX Acquisition Corp. (Nasdaq:...
Biotech firm Colossal set to return extinct bird’s egg to New Zealand
The biotech firm trying to bring extinct species back to life, Colossal Biosciences Inc., will return an egg from the flightless moa to its native New Zealand.
Good Science Is Not Enough: K4-MST To Explore At US BioTech Day, What Makes a Biotech Company Investable
An expert panel will examine why promising science is not enough and what biotech companies must prove to become financeable.
Merck to Divest CDMO Business to Lonza
Merck to Divest CDMO Business to Lonza Darmstadt, Germany, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Lonza, a global contract development and manufacturing organization, to acquire the CDMO business of Merck Transaction sharpens the focus of Merck’s Life Science business sector and provides the CDMO business with a strong platform for its next phase of development Life Science sector’s broad portfolio of consumables, technologies and services will continue to equip pharmaceutical, biotechnology and CDMO
Good Science Is Not Enough: K4-MST To Explore At US BioTech Day, What Makes a Biotech Company Investable
An expert panel will examine why promising science is not enough and what biotech companies must prove to become financeable.
Northwest Biotherapeutics Announces Keynote Presentation on Harnessing Immunity: A Personalized, Multi-Target Approach to Cancer At the UK National Health Service Annual Oncology Conference
/PRNewswire/ -- Northwest Biotherapeutics (OTCQB:NWBO) (the "Company" or "NWBio"), a biotechnology company developing DCVax® personalized immune therapies for...
In Shanghai's 'Science City,' China's ascendant biotechs make their pitch to the world
A small conference with big ambitions mirrors the rapid growth of Chinese biotech, invites comparisons to U.S. biotech gathering also known for deal-making.
UK science minister calls for more life sciences investment
UK science minister urges biopharma to invest at home after raising drug spending under US tariff deal, as watchdog probes deal’s cost.
Kos Biotechnology Partners Funds Golden Age Health for Asia Rare Disease Access
Kos Biotechnology Partners funds Golden Age Health to accelerate rare disease access in Asia, closing treatment delays for patients in Greater China and Southea
Dallas biotech investor makes big play for UNC Charlotte
RA Session II came to UNC Charlotte nearly 30 years ago, recruited as a highly touted soccer goalkeeper. He got a business degree, played pro soccer and worked for large pharma firms for a few years, then launched a career as an entrepreneur in the biotech industry. It’s a path famous for a few successes […]
Why Biotech Companies Are Becoming Top Targets for Cyber Attackers
A biotech company’s next research breakthrough is something a cyberattacker may want to steal, expose or hold for ransom. A biotech organization’s
Why do we get sleepy? Uncovering the science of sleep drive
Why do we get sleepy? A new preclinical study sheds some light on the science of sleep drive.
BioTech Social Announces Advisory Board To Advance Financial Innovation For Life Science Companies
× This page requires Javascript. Javascript is required for you to be able to read premium content. Please enable it in your browser settings. kAm k^Am kAm k^AmkAm k^AmkAm k^AmkAm k^AmkAmk6>mtIA6C:6?465 =6256CD 24C@DD 3:@E649?@=@8J[ 7:?2?46[ E649?@=@8J[ A2E:6?E 6?8286>6?E[ 4@>>F?:42E:@?D[ 2?5 4@>A2?J 3F:=5:?8 H:== 25G:D6 q$x 2D :E 3F:=5D 7:?2?4:2= :?7C2DECF4EFC6 2C@F?5 =:76 D4:6?46 :??@G2E:@?k^6>mk^AmkAmqt%wt$sp[ |5][ $6AE6>36C `f[ a_ae \ , k2 9C67lQ9EEAi^^^?6HDC@@>^Q C6=lQ?@@A6?6CQmz~#t(x#tk^2m . q:@%649 $@4:2= x?4] Wq$xX[ A2C6?E 4@>A2?J @7 q:@%649 uF?5:?8 !@CE2=[ E@52J 2??@F?465 E96 7@C>2E:@? @7 2? 25G:D@CJ 3@2C5 3C:?8:?8 E@86E96C 6IA6C:6?465 =6256CD 7C@> 3:@E649?@=@8J[ 962=E942C6[ 7:?2?46[ E649?@=@8J[ A2E:6?E 25G@424J[ 4@>>F?:42E:@?D[ 2?5 4@>A2?J 3F:=5:?8]k^AmkAm%96 25G:D@CJ 3@2C5 H:== DFAA@CE q$x’D 3C@256C >:DD:@? @7 255C6DD:?8 @?6 @7 E96 >@DE A6CD:DE6?E 492==6?86D :? =:76 D4:6?46Di 4@??64E:?8 AC@>:D:?8 :??@G2E:@? H:E9 E96 42A:E2= ?66565 E@ 25G2?46 E9C@F89 =6?8E9J 2?5 6IA6?D:G6 56G6=@A>6?E A2E9H2JD]k^AmkAmq$x :D 3F:=5:?8 7:?2?4:2= :?7C2DECF4EFC6 2C@F?5 =:76 D4:6?46 :??@G2E:@?] q:@%649 uF?5:?8 !@CE2=[ :ED $tr\C68:DE6C65 2?5 ux}#p\>6>36C #68F=2E:@? rC@H57F?5:?8 A@CE2=[ C6AC6D6?ED E96 4@>A2?J’D 7:CDE :>A=6>6?E2E:@? @7 E92E DEC2E68J] ~G6C E:>6[ q$x :?E6?5D E@ 6IA=@C6 255:E:@?2= 7:?2?4:2= DECF4EFC6D[ E@@=D[ 2?5 G69:4=6D 56D:8?65 2C@F?5 E96 5:DE:?4E:G6 42A:E2= ?665D @7 =:76 D4:6?46 4@>A2?:6D]k^AmkAm“$4:6?E:DED DA6?5 J62CD 56G6=@A:?8 D@=FE:@?D 7@C 5:D62D6D 7@C H9:49 A2E:6?ED DE:== 92G6 E@@ 76H @AE:@?D[ @?=J E@ D66 E96> 72:= 5F6 E@ 7F?5:?8 82AD 2E E96 EC2?D:E:@? :?E@ 4=:?:42= 56G6=@A>6?E” D2:5 sC] }6G2 (6DE[ rt~ 2?5 r@\u@F?56C @7 q$x] “p5G2?4:?8 E92E C6D62C49 C6BF:C6D DFDE2:?65 DFAA@CE @G6C >2?J J62CD] (6 H2?E E@ 96=A 4C62E6 2? 6?G:C@?>6?E :? H9:49 AC@>:D:?8 4=:?:42= D4:6?46[ >66E:?8 ECF6 F?>6E ?665D[ 42? 4@?E:?F6 >@G:?8 7@CH2C5 H9:=6 >F?:E:6D 27764E65 3J E96 5:D62D6 46?EC2= E@ E96 4@?G6CD2E:@?]”k^AmkAmp55C6DD:?8 E96 {:76 $4:6?46 “'2==6J @7 s62E9”k^AmkAm%96 7:?2?4:?8 492==6?86 :D A2CE:4F=2C=J 24FE6 5FC:?8 E96 D@\42==65 7F?5:?8 “G2==6J @7 562E9”[ E96 A6C:@5 :? H9:49 4@>A2?:6D >FDE 4@?E:?F6 :?G6DE:?8 :? C6D62C49[ 4=:?:42= 56G6=@A>6?E[ C68F=2E@CJ H@CA2?J 3F:=5:?8[ @7E6? 367@C6 E96J 42? 86?6C2E6 >62?:?87F= 4@>>6C4:2= C6G6?F6 @C 2EEC24E EC25:E:@?2= :?DE:EFE:@?2= 42A:E2=]k^AmkAmq$x =2F?4965 q:@%649 uF?5:?8 !@CE2= :? yF?6 a_ae 2D 2 C68F=2E65 :?G6DE>6?E 4C@H57F?5:?8 A@CE2= 3F:=E DA64:7:42==J 7@C =:76 D4:6?46 4@>A2?:6D] %96 A@CE2= 6?23=6D 6=:8:3=6 4@>A2?:6D E@ C2:D6 FA E@ Sd >:==:@? :? 42A:E2= 2??F2==J 7C@> :?5:G:5F2= :?G6DE@CD F?56C #68F=2E:@? rC@H57F?5:?8 H9:=6 4C62E:?8 @AA@CEF?:E:6D 7@C 2 3C@256C A@AF=2E:@? @7 :?G6DE@CD E@ A2CE:4:A2E6 :? AC:G2E6 =:76 D4:6?46 :??@G2E:@?]k^AmkAmq$x G:6HD E96 A@CE2= 2D E96 368:??:?8 @7 2 =2C86C 677@CE]k^AmkAm“q:@%649 uF?5:?8 !@CE2= :D @FC 7:CDE :>A=6>6?E2E:@?[ ?@E E96 6?5A@:?E[” D2:5 qC:2? !] r9C:DE:6[ r92:C 2?5 r@\u@F?56C @7 q:@%649 $@4:2= x?4] “~FC 3C@256C @3;64E:G6 :D E@ 3F:=5 7:?2?4:2= :?7C2DECF4EFC6 2C@F?5 E96 D4:6?46[ 56G6=@A:?8 7:?2?4:?8 >6492?:D>D E92E 36EE6C >2E49 42A:E2= E@ E96 >:=6DE@?6D[ C:D6?E]”k^AmkAmr9C:DE:6 25565[ “rC@DD:?8 E96 G2==6J @7 562E9 :D ?@E D:>A=J 2 7F?5C2:D:?8 AC@3=6>] %96 42A:E2= 92D E@ H@C< H:E9:? 2 >F49 =2C86C DJDE6> :?G@=G:?8 D4:6?E:7:4 >:=6DE@?6D[ C68F=2E@CJ A2E9H2JD[ A2E:6?ED[ DEC2E68:4 A2CE?6CD[ 4@>A2?J =6256CD9:A[ 2?5 :?G6DE@C 6IA64E2E:@?D] %92E :D @?6 C62D@? H6 H2?E65 2? 25G:D@CJ 3@2C5 H:E9 DF49 2 H:56 C2?86 @7 6IA6C:6?46]”k^AmkAmp |F=E:5:D4:A=:?2CJ p5G:D@CJ q@2C5k^AmkAm%96 25G:D@CJ 3@2C5 3C:?8D E@86E96C =6256CD H9@ 92G6 3F:=E 2?5 7:?2?465 4@>A2?:6D[ 56G6=@A65 3:@E649?@=@8J A2CE?6CD9:AD[ ?2G:82E65 C68F=2E65 >2CF?:E:6D[ >2?2865 4@CA@C2E6 C6AFE2E:@?[ 2?5 2DD6>3=65 =6256CD9:A E62>D]k^AmkAm%96 8C@FA :?4=F56D sC] x>25 p;;2H:[ q@3 q2C:49[ y@9? r@FC:4[ z2C:? w6==DG:6?6?4:2 ~CE:K[ (:==:2> $49C256C[ 2?5 p?5C6H (:==:D]k^AmkAmsC] x>25 p;;2H:[ p5G:D@C[ :D rt~ 2?5 r@\u@F?56C @7 #J3@sJ?[ 2 3:@E649?@=@8J 4@>A2?J 56G6=@A:?8 42?46C :>>F?@E96C2A:6D E2C86E:?8 2 4CJAE:4 AC@E6@>6] !C6G:@FD=J[ 96 H2D ':46 !C6D:56?E @7 qFD:?6DD s6G6=@A>6?E 2E p3D4:[ H96C6 96 5C@G6 >@C6 E92? Se__ >:==:@? :? A2CE?6CD9:AD 2?5 A=2J65 2 C@=6 :? E96 4@>A2?J’D S`]d 3:==:@? x!~] w6 2=D@ 4@\7@F?565 px\5C:G6? AC@E6:? 56D:8? 4@>A2?J s6?@G:F>[ H9:49 H2D 24BF:C65 3J p3D4:] p;;2H: 9@=5D 2 !9s :? q:@496>:DECJ 2?5 |@=64F=2C q:@=@8J 2?5 2? |qp 7C@> E96 #25J $49@@= @7 |2?286>6?E 2E &r $2? s:68@]k^AmkAmq@3 q2C:49[ p5G:D@C[ :D 2? 6I64FE:G6 D62C49 AC@76DD:@?2= H:E9 >@C6 E92? ae J62CD @7 6IA6C:6?46 C64CF:E:?8 4@>>F?:42E:@?D[ AF3=:4 C6=2E:@?D[ :?G6DE@C C6=2E:@?D 2?5 8@G6C?>6?E 2772:CD =6256CD] %9C@F89 r}# $62C49[ 96 H@C =6256CD9:A ?665D] w:D 6IA6C:6?46 DA2?D &]$] 2?5 :?E6C?2E:@?2= >2C246FE:42= 2?5 962=E942C6 4@>>F?:42E:@?D[ 4@?DF>6C AC@5F4ED 2?5 7:?2?4:2= D6CG:46D]k^AmkAmy@9? r@FC:4[ p5G:D@C[ 3C:?8D >@C6 E92? 7@FC 564256D @7 6IA6C:6?46 24C@DD 7:?2?46[ 32?@?E@CJ x?E6C7:?2?4:2= }6EH@C 7C@> :ED 62C=J J62CD E9C@F89 :ED 8C@HE9 :?E@ 2 7:?2?4:2= D6CG:46D ?6EH@C< DFAA@CE:?8 E9@FD2?5D @7 :?DE:EFE:@?D ?2E:@?H:56] t2C=:6C[ 96 96=5 =6256CD9:A A@D:E:@?D 2E !$x}6E 2?5 q6== pE=2?E:4[ ?@H '6C:K@? 2?5 AC6G:@FD=J H@C>:DD:@? W$trX] w6 9@=5D 2? |qp 7C@> %96 v6@C86 (2D9:?8E@? &?:G6CD:EJ 2?5 2 q$ :? r@>>6C46 7C@> E96 &?:G6CD:EJ @7 ':C8:?:2]k^AmkAmz2C:? w6==DG:D] (:==:D D6CG6D @? E96 w62=E942C6 2?5 !92C>246FE:42= |2?286>6?E !C@8C2> p5G:D@CJ q@2C5 2E r@=F>3:2 qFD:?6DD $49@@= 2?5 E96 q@2C5 @7 p5G:D@CD 2E v6@C86E@H? &?:G6CD:EJ’D |4s@?@F89 $49@@= @7 qFD:?6DD] w6 62C?65 2 q$qp 7C@> v6@C86E@H? &?:G6CD:EJ 2?5 2 ys 2?5 |qp 7C@> r@=F>3:2 &?:G6CD:EJ]k^AmkAmu:?2?4:2= |@56=D s6D:8?65 pC@F?5 w@H {:76 $4:6?46D s6G6=@Ak^AmkAm{:76 D4:6?46 4@>A2?:6D 5:776C 7F?52>6?E2==J 7C@> >2?J @E96C 6>6C8:?8 3FD:?6DD6D] r2A:E2= C6BF:C6>6?ED 2C6 7C6BF6?E=J 5C:G6? 3J D4:6?E:7:4[ 4=:?:42= 2?5 C68F=2E@CJ >:=6DE@?6D C2E96C E92? 4@?G6?E:@?2= C6G6?F6 8C@HE9] s6G6=@A>6?E E:>6=:?6D 42? DA2? J62CD[ 2?5 D:8?:7:42?E 6?E6CAC:D6 G2=F6 >2J 36 4C62E65 H6== 367@C6 2 AC@5F4E C62496D E96 >2C@56=D E92E >@C6 4=@D6=J C67=64E 9@H =:76 D4:6?46 :??@G2E:@? 24EF2==J AC@8C6DD6D]k^AmkAm“u@C >6[ E9:D F=E:>2E6=J 4@>6D 324< E@ D4:6?46 2?5 E96 A6@A=6 :E :D :?E6?565 E@ D6CG6[” (6DE D2:5] “!2E:6?ED 2?5 A2E:6?E 4@>>F?:E:6D @7E6? F?56CDE2?5 3@E9 E96 FC86?4J @7 F?>6E ?665 2?5 E96 C62=:E:6D @7 =:G:?8 H:E9 5:D62D6 :? H2JD E92E 42? 255 :>A@CE2?E A6CDA64E:G6 E@ E96 56G6=@A>6?E AC@46DD 2?5 E96J D9@F=5 36 23=6 E@ :?G6DE :? E96D6 4@>A2?:6D] pD H6 E9:?< 23@FE ?6H H2JD E@ DFAA@CE 6>6C8:?8 =:76 D4:6?46 4@>A2?:6D[ H6 H2?E E9@D6 A6CDA64E:G6D C6AC6D6?E65 2=@?8D:56 E9@D6 @7 D4:6?E:DED[ 6?EC6AC6?6FCD[ 2?5 :?G6DE@CD]”k^AmkAmq$x 6IA64ED E96 25G:D@CJ 3@2C5 E@ AC@G:56 DEC2E68:4 8F:52?46 2D E96 4@>A2?J 56G6=@AD q:@%649 uF?5:?8 !@CE2= 2?5 6G2=F2E6D 255:E:@?2= 2AAC@2496D E@ 6IA2?5:?8 2446DD E@ 42A:E2= 7@C =:76 D4:6?46 4@>A2?:6D]k^AmkAm“~FC 7@4FD :D DEC2:89E7@CH2C5[” r9C:DE:6 D2:5] “%96C6 :D C6>2C6C8:?8 4@>A2?:6D[ 2?5 E@@ >F49 @7 :E 6?4@F?E6CD 2 7:?2?4:?8 82A 367@C6 :ED A@E6?E:2= 42? 36 G2=:52E65] (6 H2?E E@ 3F:=5 7:?2?4:2= :?7C2DECF4EFC6 E92E 8:G6D >@C6 @7 E92E D4:6?46 2? @AA@CEF?:EJ E@ >2A2?J 56G6=@AD A=2E7@C>D[ E@@=D[ 2?5 7:?2?4:2= DECF4EFC6D :?E6?565 E@ 6IA2?5 2446DD E@ 42A:E2= 7@C 3:@E649?@=@8J[ A92C>246FE:42=[ >65:42= E649?@=@8J[ 5:28?@DE:4[ 5:8:E2= 962=E9[ 2?5 @E96C =:76 D4:6?46 4@>A2?:6D] q:@%649 $@4:2= x?4] :D E96 A2C6?E 4@>A2?J @7 q:@%649 uF?5:?8 !@CE2= {{r]k^AmkAmu@C >@C6 :?7@C>2E:@?[ G:D:Ei k2 9C67lQ9EEADi^^HHH]3:@E649]D@4:2=Qm9EEADi^^HHH]3:@E649]D@4:2=k^2mk^AmkAmp3@FE q:@%649 uF?5:?8 !@CE2=k^AmkAmq:@%649 uF?5:?8 !@CE2= :D 2? $tr\C68:DE6C65 7F?5:?8 A@CE2= 2?5 ux}#p >6>36C 7@4FD65 6I4=FD:G6=J @? =:76 D4:6?46 4@>A2?:6D C2:D:?8 42A:E2= F?56C #68F=2E:@? rC@H57F?5:?8] %96 A@CE2= 6?23=6D 6=:8:3=6 4@>A2?:6D E@ C2:D6 FA E@ Sd >:==:@? :? 42A:E2= 2??F2==J 7C@> :?5:G:5F2= :?G6DE@CD H9:=6 AC@G:5:?8 :?G6DE@CD 2446DD E@ AC:G2E6 =:76 D4:6?46 :?G6DE>6?E @AA@CEF?:E:6D F?56C #68F=2E:@? rC@H57F?5:?8]k^AmkAmx?G6DE>6?E @AA@CEF?:E:6D @776C65 E9C@F89 q:@%649 uF?5:?8 !@CE2= 2C6 DA64F=2E:G6[ :==:BF:5[ 2?5 :?G@=G6 2 9:89 568C66 @7 C:D6?E] %9:D AC6DD C6=62D6 :D 7@C :?7@C>2E:@?2= AFCA@D6D @?=J 2?5 5@6D ?@E 4@?DE:EFE6 2? @776C E@ D6== @C D@=:4:E2E:@? @7 2? @776C E@ 3FJ 2?J D64FC:EJ] p?J D64FC:E:6D @776C:?8 4@?5F4E65 E9C@F89 q:@%649 uF?5:?8 !@CE2= :D >256 @?=J AFCDF2?E E@ 2AA=:423=6 @776C:?8 >2E6C:2=D 7:=65 H:E9 E96 &]$] $64FC:E:6D 2?5 tI492?86 r@>>:DD:@?]k^AmkAmu@C >@C6 :?7@C>2E:@?[ G:D:Ei k2 9C67lQ9EEADi^^HHH]3:@E649]7F?5Qm9EEADi^^HHH]3:@E649]7F?5k^2mU?3DAjk^AmkAm|65:2 r@?E24Eik^AmkAm{66\p?? |FCA9Jk^AmkAmq:@%649 $@4:2= x?4k^AmkAmk2 9C67lQ>2:=E@i=662??o3:@E649]D@4:2=Qm=662??o3:@E649]D@4:2=k^2mU?3DAjk^AmkAm k^Am
S.D. Biotech announces annual award winners
South Dakota Biotech recognized outstanding industry partners recently with awards presented at its annual summit.
Norwest closes $4B global, multi-stage fund to fuel investments in healthcare, biotech and AI
Norwest closed a $4 billion global, multi-stage fund to continue backing technology, healthcare and consumer companies across the U.S., India and Israel. | Norwest closes $4B fund to invest in healthcare AI, biotech
2026's Fiercest Women in Life Sciences
A decade ago, the idea of using a patient's own immune cells to treat cancer was still largely experimental. Drugs that could address the underlying biology of narcolepsy had yet to reach the market. And despite decades of research, there was no broadly approved preventive treatment that could protect infants against respiratory syncytial virus through their first RSV season with a single dose. | The 10 women recognized in this year’s Fiercest Women in Life Sciences have helped develop first-in-class treatments, founded and financed biotechs, and guided experimental therapies through clinical development. In interviews with Fierce, they reflected on the decisions, setbacks and mentors that shaped their careers.
OpenAI acquires startup Orchestra Bio to beef up its biotech business
OpenAI says it's adding Orchestra's team and technology to work on Rosalind, its AI model for life sciences research, and to its related Rosalind Workbench tool, a harness that aims to help researchers plan experiments and analyze results.
How AI is rewriting the rules for medicine and biotech in Mass.
Three Mass. health care leaders explain why AI in medicine is about more than speed—it's changing how scientists and doctors approach patient care.
New Richland Lab Could Transform How Scientists Study Microbes and Boost Regional Jobs
The BriefGroundbreaking held Tuesday: PNNL officially began construction on the M2PC lab, a 30,800-square-foot facility funded by the U.S. Department of Energy's Office of Science that will study soil microbes to improve crop productivity and develop new biotechnology applications. The facility will be open to researchers from around the nation and the world.Research timelines could shrink dramatically: The facility's automation and AI capabilities could reduce experiments that currently take six months to just 72 hours, allowing scientists to explore more possibilities faster than ever before.New jobs coming to the Tri-Cities: The project is expected to create positions for automation engineers, AI experts, roboticists, technicians, and skilled craftspeople, with the facility opening in 2029.RICHLAND, Wash. — Pacific Northwest National Laboratory broke ground Tuesday on a first-of-its-kind facility that could accelerate scientific discoveries about the microscopic organisms living in soil—organisms that may hold the key to growing more food and developing new energy technologies.The Microbial Molecular Phenotyping Capability, or M2PC, represents a significant investment in automation and artificial intelligence to speed up research that traditionally takes years to complete. The 30,800-square-foot facility will house more than 100 connected automated instruments designed to study microbes at a pace and scale never before possible.Reshaping Agriculture's FutureThe M2PC facility will not put a new tool directly into a farmer's hands tomorrow morning, but it is actively reshaping the commercial pipeline to solve agriculture's biggest headache with biologicals: inconsistent field performance. For years, PNNL researchers have explored how microbes work and how they might help produce useful materials, advance energy technologies, and address challenges involving critical materials and minerals. But those experiments have been limited by what researchers could accomplish by hand."They can be used to provide nutrients to a plant so that the plant would grow more. So, like increasing your crop productivity, for example," said Douglas Mans, PNNL's Associate Laboratory Director for Integrated Discovery Sciences.PNNL's own research shows soil microbes can help plants access nutrients and withstand drought—benefits that could prove crucial as farmers face growing environmental pressures. The M2PC facility will allow scientists to identify and optimize useful microbes faster than ever before, accelerating the development of biological solutions that actually work consistently in the field.What Makes M2PC UniqueThe Microbial Molecular Phenotyping Capability differs from traditional research labs because it operates as a first-of-its-kind, AI-enabled autonomous laboratory designed to shrink experimental timelines from years down to months or weeks. The M2PC lab will connect more than 100 automated instruments to grow microbes, prepare samples, measure their behavior, and link observations to the molecular processes behind them. Artificial intelligence will help analyze results and guide the next experiments, allowing scientists to explore more questions faster.Deb Gracio, PNNL Director, emphasized the transformative potential during Tuesday's groundbreaking ceremony: "Research that has taken years will become possible in months and hopefully in weeks."That acceleration is already being demonstrated. PNNL's smaller automated lab, called the Anaerobic Microbial Phenotyping Platform or AMP2, completed three experimental cycles in just 72 hours—a process that normally would have taken about six months."That normally would have taken us about six months … and we were able to do that in 72 hours," Mans said.The AMP2 laboratory is not being closed or replaced. Instead, the current 1,800-square-foot laboratory serves as an active prototype and precursor for the much larger M2PC facility. AMP2 will continue operating as a separate lab designed to run anaerobic experiments—those conducted in the absence of oxygen—while M2PC will focus on aerobic research.Broader Applications Beyond AgricultureWhile improving crop productivity is one important application, the M2PC facility is designed to support research into multiple areas critical to national priorities. The lab will advance research into biofuels, manufacturing materials, and energy technologies. It will also help researchers understand how microbes respond to environmental changes and how to design biological systems for biotechnology applications.As a flagship component of the Department of Energy's Genesis Mission, M2PC represents a significant investment in using artificial intelligence and automation to accelerate U.S. scientific discovery. Dorothy Koch, Associate Director of the DOE Office of Science Biological and Environmental Research program, highlighted the facility's importance during the groundbreaking."M2PC will accelerate biological discovery and design," Koch said, noting that the facility is expected to conduct a minimum of 500 strain experiments per week, 100 microbiome experiments per week, and take a million measurements per month.Economic Opportunity for the RegionBeyond the scientific breakthroughs, the M2PC project represents significant economic opportunity for the Tri-Cities region. The facility will require hiring automation engineers, AI experts, technicians skilled in operating robotics, and specialized craftspeople to build and maintain the sophisticated equipment."We're anticipating that type of hiring," Mans said when asked about job creation.PNNL has already begun recruiting talent nationally and internationally for positions related to the smaller AMP2 lab, bringing automation engineers from cities like Boston and San Francisco to work in the region. The M2PC facility is expected to accelerate that trend."This capability won't really exist anywhere else in the world," Mans said, suggesting the facility could become a draw for scientific talent seeking to work on cutting-edge biotechnology research.Timeline and Next StepsThe M2PC facility is expected to open in 2029. Between now and then, construction crews will level and prepare the ground, while the building takes shape. Simultaneously, Ginkgo Bio Works, the automation contractor, will build the facility's automation components off-site so they can be installed as the building is completed.In the interim, PNNL researchers and the broader scientific community will begin planning the first experiments to be conducted in the facility, ensuring research is lined up and ready to begin as soon as the doors open.The groundbreaking ceremony included representatives from the Department of Energy, PNNL leadership, and elected officials at the federal, state, and local levels, underscoring the project's significance to the region and the nation's biotechnology future. News The U.S. Department of Energy Secretary tours Pacific Northwest National Laboratory Dan Hanson, Apple Valley News Now News Beyond DNA: Scientists Explore New Frontiers in Biology Research Dan Hanson, Apple Valley News Now News TRIDEC optimistic that Hanford, PNNL will see funding in national budget Robert Desaulniers News Big picture science: monitoring the Yakima River Basin News PNNL research could shape the future of fighting fentanyl COPYRIGHT 2026 BY APPLE VALLEY NEWS NOW. ALL RIGHTS RESERVED. THIS MATERIAL MAY NOT BE PUBLISHED, BROADCAST, REWRITTEN OR REDISTRIBUTED.
T-Cypher Bio extends footprint in purpose-built laboratory space at Abingdon Science Park, Oxford
T-Cypher Bio ("T-Cypher), a biotechnology company developing novel T cell receptor (TCR)-based T cell engagers that target high copy number antigens, today announced its relocation to Abingdon Science Park, Oxford, UK.
Xtalks Announces its Life Science Webinar Calendar for October 2026
Stay on top of current hot topics through free webinars presented by leading experts in the pharma, biotech, medical device and food industries. Access to all webinars is free, so be sure to register today to save your place! Participate in the discussion and stay relevant in your field!
DOE, NIH, and Biohub Partner to Build Foundational Data for Predictive Biological AI Models
WASHINGTON and SAN FRANCISCO, Oct. 9, 2026 — The Department of Energy’s (DOE) Office of Science, the National Institutes of Health (NIH), and Biohub signed a Memorandum of Understanding (MOU) to advance the frontier of Artificial Intelligence (AI) in biology, deepen our understanding of human health and disease, and accelerate breakthroughs in medicine and biotechnology. […]
Biotech entrepreneur Dr. Shakked Halperin invests in next generation of Israeli scientists
While Israel continues to strengthen its position as a global innovation hub, access to educational opportunities that help develop future scientists and entrepreneurs remains relatively uneven.
Merck Life Science Expands Bengaluru Manufacturing with €13 Million Investment
Merck Life Science is expanding its manufacturing capabilities in Bengaluru with an investment of approximately €13 million, strengthening the company’s ability to supply critical materials to customers across India and the wider Asia-Pacific region. The expansion at Merck Life Science’s Jigani site in Bengaluru will introduce biological buffer manufacturing alongside the facility’s established chemistry capabilities. The investment is designed to enable faster and more reliable access to critical materials used by customers across research, diagnostics, biotechnology and biopharmaceutical manufacturing. The development further advances Merck Life Science’s “in-region, for-region” approach, under which the company is expanding manufacturing capabilities closer to the markets and customers it serves. By adding biological buffer production in India, the Jigani expansion will broaden the site’s manufacturing capabilities while strengthening Merck Life Science’s regional supply infrastructure for the rapidly developing life sciences sector across India and Asia-Pacific. The company said the expansion reflects both the contribution of its teams and its collaboration with government and industry stakeholders. Merck Life Science acknowledged the support of India’s Department for Promotion of Industry and Internal Trade (DPIIT), the German Embassy New Delhi, and Invest India in helping strengthen life science manufacturing capabilities in the region. The investment comes as India continues to expand its role across pharmaceutical, biotechnology, diagnostics and biomanufacturing value chains, increasing demand for dependable regional access to materials supporting research and manufacturing operations. The Bengaluru expansion reinforces Merck Life Science’s focus on building manufacturing capacity within Asia-Pacific and supporting customers through a more regionalised supply network.
BRC expands support for life sciences research at Cornell
The Biotechnology Resource Center – a set of core facilities providing shared, cutting-edge resources for life sciences research – is enhancing and expanding its support for Cornell researchers.
Pfizer makes ‘business decision’ to end phase 2 trial of autoimmune drug as program’s future uncertain
Pfizer has called time on a phase 2 trial of its CXCR5 antibody in an autoimmune blood disorder, with the company tight-lipped on whether this marks the end of the road for the asset. The Big Pharma had been evaluating the therapy, dubbed PF-06835375, in a phase 2 study of 61 patients with primary immune thrombocytopenia (ITP) that kicked off in 2022, according to the federal trials register. However, Pfizer confirmed to Fierce on Monday that this study had been terminated “due to a business decision.” “The decision to terminate the trial was not based on any safety concerns,” a spokesperson pointed out. At time of publication, PF-06835375 remained listed on Pfizer’s website for both ITP and lupus. A phase 1 study in lupus wrapped up in 2022, according to the trials database. ITP is an autoimmune disorder characterized by a low platelet count. Novartis was at one point evaluating its B-cell-depleting antibody ianalumab—recently approved as Fabhalta to treat immunoglobulin A nephropathy—as a potential treatment ITP. But the therapy struggled to demonstrate a benefit in the clinic for this indication. When contacted by Fierce, Pfizer wouldn’t confirm whether all work on PF-06835375 has been halted, and whether the company has any other plans to explore C-X-C chemokine receptor type 5 (CXCR5) as a mechanism. CXCR5 is found in blood cancers such as diffuse large B-cell lymphoma and mantle cell lymphoma chemokine receptor. However, there is little expression in normal tissue, which has led some drug developers to explore its potential. Vincerx Pharma had at one point been planning to take an anti-CXCR5 ADC into the clinic to treat B-cell malignancies, but that ambition was scrapped due to cash constraints. Where Big Pharma is placing its bets is one of the hot topics being discussed at Fierce Biotech's high-impact event in London next month. Find out more information and register by clicking on the banner below: [ ](https://qtxasset.com/quartz/qcloud5/media/image/where_big_pharma_is_placing_its_bets.png?VersionId=B8JrRbJ.pFUSK1pJgjeWHLGm_18RdLAy)
Finding the business case for human cell therapies
How a small-cap biotech and its CFO are spending the funds from big-name partners.
Alnylam bulls and bears fight it out after business-shaking guidance cut
While Alnylam’s recent reduced revenue guidance spooked investors, analysts remain broadly bullish on the biotech’s commercial prospects.
China is excelling in health tech. That’s good news for the world
Ruby Wang, a physician and biotech consultant in the U.K., on her upcoming book on the emergence of China as a global health superpower.
Where Life Science Scales in Basel
The Basel region is one of the world’s leading life-science clusters. Pharmaceutical companies, biotech firms and research institutions benefit from a unique combination of talent, infrastructure and international collaboration. As the industry continues to grow, the demand for scalable laboratory and office environments within this innovation ecosystem is increasing.
How Biotech AI And Robotics Bridge Bottlenecks To Impact Global Health
While biotech increasingly adopts AI for R&D, manufacturing bottlenecks constrain health innovation. AI and robotics have the potential to unlock health impact globally.
Pioneer of China NewCo model sued in US over trade secret misuse, double-dealing
A legal feud unfolding in New York is putting a spotlight on the work of a business development veteran who is credited for pioneering one of biopharma’s hottest dealmaking mechanism: the China “NewCo” model. In a lawsuit originally filed in New York state court and recently moved to federal court, China’s Lepu Medical Technology has alleged that biopharma business development consultant Su Zhang, who was hired to help shop its GLP-1 weight-loss candidates to Western partners, engaged in corporate double-dealing and trade secret leaks. According to the complaint, while acting as Lepu’s primary dealmaking liaison for a group of obesity and metabolic disease drug candidates, Zhang was secretly double-dipping as the acting chief business officer for a direct competitor, BrightGene Pharmaceutical. “She never adequately disclosed the role, never sought Lepu’s consent, and never proposed any safeguard,” Lepu alleged in its complaint, which was filed in July after Zhang’s consulting firm, CoDevCo, sought certain transaction-based success fees from its angry customer through an arbitration process in Singapore. Lepu, the parent company of Lepu Biopharma, has asked Zhang to pay back its $500,000 retainer and disgorge all benefits she received during the alleged breaches of fiduciary duty, plus other damages and relief. The company has also requested the court grant injunctions to protect Lepu’s trade secrets. The ill-fated partnership officially kicked off in December 2024, when Lepu tapped CoDevCo as its “exclusive business development mechanism” to identify collaborators for the company’s drug candidates. According to Lepu’s complaint, Zhang personally negotiated and signed the agreement as managing director for CoDevCo, which used her home address. Before the Lepu deal, Zhang made a name following a short stint as the global head of business development for Hengrui Pharmaceuticals. It was during her tenure that Hengrui signed a landmark deal granting exclusive rights for a portfolio of GLP-1 assets to Hercules, which was at that time newly established by a group of private equity and venture capital firms. In addition to the regular upfront and milestone payments, Hengrui also gained an equity stake in Hercules, which later became Kailera Therapeutics. The Hengrui-Hercules deal opened a new paradigm, where a Chinese biopharma company spins off certain early-stage assets to investors for further development through the creation of a new company abroad. The “NewCo” model quickly came into vogue as it allows Western investors to access high-potential assets originating from China at an early stage while giving the Chinese licensors an opportunity to reap long-term benefits through equity stakes in the new firms. The NewCo model proved its value when Kailera staged a record-breaking $625 million IPO on Nasdaq this April, merely two years into the Hengrui deal. Related Kailera CEO 'knew we were in a good spot' before obesity biotech's record-breaking $625M IPO On her LinkedIn page, Zhang described her work at Hengrui as “[b]uilding team and capability from the ground up,” forming NewCo and major pharma partnerships worth billions of dollars. Lepu clearly wanted that kind of track record to help boost its own cardiometabolic portfolio, which includes a range of assets for obesity, Type 2 diabetes, fatty liver disease and muscle preservation during weight loss treatment. “Lepu’s pipeline is very valuable, but only if Lepu could secure the right international partner to expand into the overseas market during the available commercial window,” the company argued in its complaint. The Chinese biotech said it had little knowledge of U.S. laws, customs or business practices in the business development field, and therefore “needed to rely entirely” on the expertise of Zhang and her team as the firm’s first engagement of a U.S.-based BD consultant. “Zhang’s dominating influence on the business development strategy is further evidenced by the fact that she personally controlled the business-development communications on behalf of Lepu with potential partners,” Lepu said in its complaint. After entering the deal, Zhang introduced Lepu to her four associates. According to Lepu’s version of events, all of them were allegedly employed at different time points to perform similar jobs at other Chinese companies that Lepu described as its competitors, while having access to Lepu’s confidential information. As such, Lepu described Zhang’s team as “a roster of individuals whose primary professional loyalty, by virtue of their concurrent full-time employment, ran to Lepu’s competitors.” As well as the specific examples set out in the case, a look at Lepu’s deals over the period suggests Zhang may have been involved in at least one transaction. During their partnership, Lepu, through its subsidiary Shanghai Minwei Biotechnology, also out-licensed its GLP-1/GIP/FGF21 agonist MWN105 to a NewCo called Sidera Bio in the fall of 2025. The deal included an upfront and near-term payment of $35 million, up to $1.01 billion in milestones, and a 9.99% stake in the Danish startup. It seems likely that Zhang facilitated the Minwei deal given that Lepu is on record as having used CoDevCo as its “exclusive business development mechanism.” The big shock for Lepu came in the form of a news article on June 25, 2025. The article, reporting on phase 2 data for BrightGene’s GLP-1/GIP receptor agonist BGM0504, identified Zhang as acting chief business officer of the Lepu rival. Blindsided by her association with BrightGene, Lepu confronted Zhang in July 2025. “Lepu was given assurances that there was nothing to be concerned about and told that Zhang would explain the matter to Lepu,” Lepu alleged in its complaint. “Zhang never did.” Lepu claimed that Zhang had the motive and opportunity to steer potential prospective partners toward BrightGene or other competitors. Later, in February 2026, one of Zhang’s associates joined BrightGene as the vice president for global business development, according to the complaint. Around the same time, Lepu sent written demand letters asking Zhang to account for her BrightGene role, identify what confidential data were shared with the rival firm, and provide any conflict-of-interest or firewall policies during the engagement. According to Lepu, neither CoDevCo nor Zhang answered the questions in their responses. Related Novo vs. KBP: How a $1.3B deal turned into a fraud accusation and an international legal fight In a motion to dismiss filed with the U.S. District Court in the Eastern District of New York on Sept. 4, Zhang’s legal team argued that Lepu’s agreement was signed with CoDevCo, and that an employee of the contractor does not owe fiduciary duties to the client. In its complaint, Lepu said: “That CoDevCo was the contracting entity does not insulate Zhang from personal liability for duties she personally undertook and personally breached.” Taking the argument one step further, the defending party argued that the consulting agreement “does not create a fiduciary relationship even between CoDevCo and Lepu; instead, it identifies CoDevCo as an independent contractor retained to market Lepu’s business to potential western partners.” Although CoDevCo was Lepu’s exclusive business-development contractor, there were no terms stipulating that the consulting firm should serve only Lepu, Zhang’s lawyer noted. As to Lepu’s claims that Zhang misappropriated trade secrets, the defendant argued that Lepu authorized the use of the information so Zhang’s team could perform their service per the agreement. In a rebuttal filed on Sept. 11, Lepu’s lawyer set out why they believe the Chinese biotech satisfied New York law’s misappropriation definition by alleging that the defendant used a trade secret “in breach of a duty or through improper means.” As an alternative to dismissing the suit, the defendant suggested the action should be stayed pending outcomes from the arbitration of a separate case in Singapore. While NewCo pioneer Zhang is defending her business arrangements, momentum behind the NewCo trend has continued unabated into 2026. Through August, Chinese biotech assets have spurred 15 NewCo deals this year, according to local trade publication PharmaDJ.
Fresenius: 'We are doubling down on our biopharma business'
German health-care group Fresenius has entered into a deal with Chinese biotech firm WuXi Biologics in what it called a "doubling down" on its biopharma business. The exclusive development agreement provides Fresenius access to up to 37 identified biosimilar candidates over the next decade.
Oxford Science Enterprises targets UK’s first trillion-pound deep-tech company
Recent landmark exits in quantum computing and biotech show that the OSE’s model of building companies around university research, recruiting entrepreneurial leaders and providing patient capital produces results. The next step is taking the model global.
BioNTech founders receive science award
The founders of German biotechnology company BioNTech, Özlem Türeci and Uğur Şahin, have been honored with a prestigious scientific award named after Turkish Nobel laureate Aziz Sancar.
‘High tide’ of China biotech deals seen as US curb fears fade: analysts
Stocks jump on reports Washington will allow most licensing deals under ‘substantially softer stance’ than had been feared, analysts say.
UNR launches animal science program to keep students in-state
University of Nevada, Reno launches a new bachelor's degree in animal science to train students for livestock and biotech careers.
In Shanghai’s ‘Science City,’ China’s ascendant biotechs make their pitch to the world
For two years, American labs and board rooms have been riven with excitement and anxiety over the vertiginous rise of Chinese biotech.
Your face gets antiaging science. Now what?
Core Biogenesis and Faravelli are testing whether the biotech behind facial skincare can be scaled up to treat the rest of the body.
NeuroSense Provides Business Update and Progress for the First Half of 2026
/PRNewswire/ -- Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense" or the "Company"), a late-stage clinical biotechnology company focused on developing...
Health Brief: Making sense of Treasury’s biotech deal proposal
Pharma sees a potential catch in Washington’s latest effort to curb China’s biotech ambitions
Vietnamese scientist wins ASEAN-US Science Prize for Women
Associate Professor Ha Thị Thanh Huong graduated with top grade in biotechnology from the University of Science under Vietnam National University, HCM City.
INOVIO Announces Favorable Judgment in Litigation with VGXI, Inc. and GeneOne Life Science
/PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and...
Anthropic's IPO filing shows how it's boosting biotech research
Anthropic's S-1 filing says Claude can accelerate drug discovery and biology research, making life sciences central to the AI company's IPO pitch.
How biotechnology can build food self-sufficiency
Hiring in NH’s life sciences industry is growing quicker than the rest of New England
The life sciences industry is a small but expanding part of the state’s economy, and includes medical device manufacturers, pharmaceutical manufacturers, and biotechnology researchers.
SMC's Distinguished Scientists Series Returns: Biotech & USC Talks
Free science lectures at Santa Monica College on Oct. 20 and Nov. 19 featuring biotech executives and USC researchers discussing precision medicine and gene therapy.
Valerio Therapeutics Provides an Update on Its Business and Presents Its Financial Results for the First Half of 2026
VILLEJUIF, France, October 07, 2026--Regulatory News: Valerio Therapeutics (FR0010095596 - ALVIO), a pioneering biotechnology company in the field of next-generation precision therapies ("Valerio", or the "Company"), provides an update on its operations and presents its financial results for the half-year ended 30 June 2026.
National High Magnetic Field Laboratory will develop cutting-edge nuclear magnetic resonance facility with $18M in funding
The project supports National Science Foundation priorities in biotechnology, energy, advanced manufacturing and health The National High Magnetic Field
This grad’s company helps drugs get developed faster and cheaper
Flow cytometry services help biotech startups test new drugs. A Northeastern Ph.D. grad built SauveBio to make them cheaper.
Northwest Biotherapeutics and the UK National Health Service Blood and Transplant Announce Collaboration to Support DCVax®-L Production
/PRNewswire/ -- Northwest Biotherapeutics (OTCQB:NWBO) (the "Company" or "NWBio"), a biotechnology company developing DCVax® personalized immune therapies for...
Xtalks Announces its Life Science Webinar Calendar for October 2026
/PRNewswire/ -- Stay on top of current hot topics through free webinars presented by leading experts in the pharma, biotech, medical device and food industries....
Bioeconomy Needs Supply Chains and Science: David Zilberman
UC Berkeley economist David Zilberman outlines how biotechnology, circular supply chains, and regulation are vital to scale the global bioeconomy.
Buzzy Holmes doc wins slow Halloween box office in N. America
"You Can See Everything," the documentary about jailed biotech fraudster Elizabeth Holmes that is generating major Oscars buzz, prevailed in a slow weekend at the Halloween box office in North America...
ESMO: Roche touts ‘convincing’ phase 3 KRAS data after win over rivals
Roche has shed more light on its investigational KRAS G12C inhibitor's phase 3 victory over Amgen’s Lumakras and Bristol Myers Squibb’s Krazati. The open-label Krascendo 1 trial enrolled 338 people with previously treated KRAS G12C-mutated non-small cell lung cancer (NSCLC). Patients who had already received a KRAS G12C inhibitor or pan-KRAS/RAS inhibitor were excluded from the trial. Participants received either divarasib once daily, Lumakras once daily or Krazati twice daily. Roche announced back in July that divarasib had demonstrated statistically significant improvements in progression-free survival (PFS) and overall survival (OS), meeting the trial’s primary and key secondary endpoints. But the Swiss pharma had been holding back the detailed data until now. At the European Society for Medical Oncology (ESMO) Congress in Madrid, Roche revealed that median OS for the 167 patients who received divarasib was 17.7 months, compared to 12 months for the 171 patients who received Lumakras or Krazati. The benefit was similarly clear when it came to median PFS, which stood at 9.8 months versus 5.7 months, respectively. A total of 44% of patients receiving divarasib were alive without disease progression at one year, compared to 24% of the control group, according to Roche’s presentation. It was a similar story for the objective response rate, which came in at 58% for divarasib versus 32% for the control group, while median duration of response was 11.9 months versus 6.9 months. Stefan Frings, M.D., Ph.D., deputy chief medical officer at Roche Pharma, told Fierce that the data made for a “very comprehensive, strong package, which should be convincing to health authorities.” “It’s an important advance for patients with lung cancer,” Frings said in an interview at a Madrid hotel during the conference. “It's a second-line setting, and patients who receive divarasib benefit compared to the current first-generation KRAS G12C inhibitors by having far longer overall survival,” he continued. “They live longer. They have better progression-free survival, better response rates, and with a safety profile which is—if [anything]—even better,” he said. According to Roche, 4.8% of patients receiving divarasib discontinued treatment due to treatment-related adverse events, compared to 11.7% in the control group. Serious treatment-related adverse events were also less common with divarasib, at 7.8% versus 15.2%. Roche’s confidence in divarasib had been building even before this phase 3 success. The candidate had already shown better potency and selectivity than the incumbent KRAS G12C inhibitors Krazati and Lumakras in preclinical tests. After cross-trial comparisons suggested that the edge translated into better clinical outcomes, Roche axed a study comparing divarasib to the chemotherapy docetaxel and went toe-to-toe with Lumakras and Krazati. “We designed the drug on purpose with higher potency and better selectivity,” Frings explained. “So, based on preclinical models, we clearly knew it would be superior to the first generation.” “It’s honestly not so frequent that pharma companies go head-to-head,” he added. “But if you want to make a point, if you want to convince payers, prescribers and patients … then a head-to-head win is rather rewarding.” While Amgen and BMS reached the regulatory finish line first for KRAS G12C-mutated, locally advanced or metastatic NSCLC in 2021 and 2022, respectively, they have struggled to capitalize on their head start. Krazati brought in $55 million for BMS in the second quarter, while Lumakras delivered $111 million to Amgen. For its part, Roche is aiming for peak divarasib sales of 1 billion to 2 billion Swiss francs ($1.2 billion to $2.5 billion), according to Frings. The Big Pharma is currently recruiting patients into a phase 3 trial comparing divarasib plus Keytruda against Keytruda plus chemotherapy in previously untreated advanced or metastatic nonsquamous KRAS G12C-mutated NSCLC. Roche has previously suggested that sales in metastatic disease would account for most of the forecast. Frings was tight-lipped on the exact timeline for a regulatory filing but said the Swiss pharma is “certainly keen to get this to as many patients as possible around the world.” Roche has more RAS drugs coming up behind divarasib. The pharma has already launched phase 1 trials of a pan-RAS inhibitor called RG6505 and a KRAS G12D inhibitor dubbed RG6620 in solid tumors. Roche’s partner Chugai Pharmaceutical is also testing a pan-KRAS inhibitor called AUBE00. Roche has made a “deliberate effort” to test a range of RAS drugs, Frings said. “If you have many rare mutations and you are scrambling to find sufficient patients, a pan-RAS inhibitor makes a lot of sense,” he explained.
This week in health care policy: November 6-13
Drug pricing and innovation Biotech groups sue CMS over the GLOBE model. Three biotech groups sued CMS over the Global Benchmark for Efficient Drug Pricing (GLOBE) model, which would require manufacturers to provide rebates on certain Part B drugs in an effort to match prices in foreign countries. They argue CMS exceeded its authority to […]
Cuban scientists produce first horse cloned entirely in Chile
Two Cuban scientists based in Chile have produced the first horse cloned entirely in the country, a breakthrough in local reproductive biotechnology.
Call for Abstracts — 2027 Petrie-Flom Center Annual Conference: Generative AI in Healthcare: Law & Regulation - Petrie-Flom Center
The Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School is pleased to announce our 2027 Annual Conference, Generative AI in Healthcare: Law and Regulation. Generative AI –- artificial intelligence designed to produce output, such as text or images, that normally require human intelligence — has become a…
Europe has the science. Now it needs a clinical trials system to match.
Europe has the scientific expertise to lead the next generation of cancer research, but slow and fragmented clinical trial processes, particularly in the case of multinational trials, are not allowing it to reach its full potential. The EU Biotech Act can address the existing bottlenecks to turn this excellence into faster research, stronger competitiveness and earlier opportunities for patients.
Scientists challenge the dream of bringing extinct species back to life
Could extinction itself become a thing of the past? Advances in biotechnology, including ancient DNA sequencing, genome analysis and gene editing, have led some to believe that it may be possible to bring ...
How science diplomacy is strengthening US-Italy tech ties
From biotechnology to artificial intelligence, Rome and Washington are deepening cooperation in strategic technologies. ISSNAF President Luca Pani tells Healthcare Policy how Italy’s scientific diaspora can help bridge the two innovation ecosystems and accelerate transatlantic technology transfer
Studying Science in an Anti-Scientific Time
This Chronicle Review Deep Cut was first published in 2025. By Julianne Werlin Thanks for reading The Chronicle Review! Subscribe for free to receive new posts and support my work. Subscribe The last two decades have not been kind to science studies. Already bruised and battered by the “science wars” of the 1990s, by the 2000s sociologists of science — who had long argued that science had to be understood in its human context — were encountering the funhouse-mirror version of their own views in right-wing critiques of climate scientists. It was enough to give some prominent scholars pause. “Was I wrong to participate in the invention of this field known as science studies?” asked Bruno Latour, the most famous sociologist of science in the world, in 2003. “Should we apologize for having been wrong all along? Or should we rather bring the sword of criticism to criticism itself and do a bit of soul-searching here: What were we really after when we were so intent on showing the social construction of scientific facts?” In response, Latour proposed a change of method and attitude. Science studies, now chastened and contrite, would no longer seek to strip facts of their authority, but to enrich and enhance them. What this meant in practice was never fully clear. But his diagnosis of problems resonated, even if his solutions did not. Latour’s exercise in public hand-wringing signaled a shift in mood. By 2016, with the first election of Donald Trump, the idea that skepticism of science was a right-wing position, not a left-wing one, had become a commonplace, discussed eagerly in The New York Times. For liberals, vaccine denial during the Covid era and Trump’s second-term attacks on the funding of scientific research, covered extensively in these pages, added a new urgency to the defense of science on both practical and principled grounds. There was little appetite for a sociology or philosophy of science that emphasized the messiness and missteps of the scientific process rather than its integrity and triumphs. The distinguished historian of science Peter Dear’s new book, The World as We Know It: From Natural Philosophy to Modern Science (Princeton University Press, 2025), which seeks to tell the story of 18th- and 19th-century science for a general public, may seem comfortably remote from these bitter contests. In its 16 short chapters, Dear draws swift, sure sketches of major discoveries from Newton to Einstein, ably guiding the reader through debates on stellar nebulae, animal taxonomy, atomic chemistry, evolution, and other flashpoints in the history of science. But though a work of history, Dear’s book must still negotiate our polarized present. In a blurb on its back cover, the historian of biology Lynn K. Nyhart alludes to the “present moment, when scientific knowledge is being swamped by misinformation and its institutions are under siege.” Dear himself, in his conclusion, refers to the “yard signs” and “bumper stickers” that proclaim “Science Is Real.” One antidote to both anti-science propaganda and to reductive slogans in science’s defense is a robust history and philosophy of science: exactly what Dear’s scholarship has long offered. But his new book illustrates how difficult such work has become. Dear, an emeritus professor of history at Cornell University, is best known as a creative and philosophically minded historian of the Scientific Revolution. His edited volume The Literary Structure of Scientific Argument (1991) analyzed the rhetoric of Galileo’s thought experiments to brilliant effect. Discipline and Experience: The Mathematical Way in the Scientific Revolution (1995) was a major contribution to the analysis of scientific experiments in early modern Europe and beyond, while Revolutionizing the Sciences: European Knowledge in Transition, 1500-1700 (2001), now in its third edition, remains one of the best overviews of the profound epistemological upheavals of 16th- and 17th-century science. But Dear has also ventured into later periods. Nearly two decades ago, in The Intelligibility of Nature: How Science Makes Sense of the World (2006), he turned to the 18th and 19th centuries to sketch a history and theory of scientific knowledge. Aimed at a generalist audience, Dear’s simple prose belied serious philosophical ambitions. Science, Dear argued, has two aspects: “natural philosophy,” the quest to understand the true nature of the universe, and “instrumentality,” the applied skills and technologies that allow us to manipulate the world for human advantage. Both strands are ancient, but the innovation of the phenomenon we call “science” was to yoke them together. As Francis Bacon wrote, “Human knowledge and human power meet in one; for where the cause is not known, the effect cannot be produced,” an insight typically abridged to “knowledge is power.” Or, in Bertrand Russell’s characteristically blunt phrase, science has two functions, “1. to enable us to know things, and 2., to enable us to do things.” So far, so conventional. But Dear took issue with this familiar story in one respect. Bacon’s formula implied that theory and practice could be fused in a single method. In fact, Dear argued, the quest to understand nature and the desire to manipulate it were coupled only loosely. They could come together, but they could also pull apart. Focusing on natural philosophy, the “knowing” half of the scientific circle, he used a series of case studies from cosmology, taxonomy, chemistry, electromagnetism, and quantum theory to show how theories changed over time, in dialogue with practice, but never reducible to it. Take the case of matter, the basic substrate of the physical world. In the 18th and 19th centuries, scientists not only disagreed about what it was, but also about how well it could be known. In 1789, the chemist Antoine Lavoisier dismissed speculation about the atomic composition of chemicals as “discussions entirely of a metaphysical nature,” as he sought to orient chemistry away from philosophical abstraction and toward laboratory results. But in the 19th century, atoms returned with a vengeance in the atomic chemistry of John Dalton, who wanted to explain the underlying structure of nature. It was not just that Dalton and Lavoisier had a different set of experimental results, or even a different theory, Dear showed. What counted as an explanation had changed. In arguing that scientific theories depended on their intelligibility to human beings with complex arrays of beliefs and commitments, Dear was in sympathy with science studies. Key figures such as the sociologist Steven Shapin emphasized the importance of psychological mechanisms like trust in the formation and acceptance of scientific ideas. But in focusing on the scientific pursuit of knowledge, not its politics or economics, Dear resisted the more cynical perspective of some of his colleagues. The Intelligibility of Nature strikes a very different note than Shapin’s collection of a few years later, Never Pure: Historical Studies of Science as If It Was Produced by People With Bodies, Situated in Time, Space, Culture, and Society, and Struggling for Credibility and Authority (2010), to name just one example. Walking a very fine line, Dear depicted science as driven at once by complex social dynamics and by the intellectual power of real discoveries. It was a testament not only to his own acumen but also to the vitality of the field that he was able to do so. Nearly two decades later, The World as We Know It returns to the questions broached in The Intelligibility of Nature. Like Dear’s earlier study, it begins with the Newtonian cosmos and ends with debates between Einstein and Bohr on quantum physics. Beyond its terminal figures, many of the same characters appear in both studies, including the naturalists John Ray and the Comte de Buffon; the chemists Étienne François Geoffroy, Antoine Lavoisier, and John Dalton; as well as Charles Darwin and Michael Faraday, among others. Its subject is nearly identical: As in The Intelligibility of Nature, The World as We Know It considers natural philosophy as opposed to instrumentality, here defined as the “desire to create a picture of what the world is really like — the world as God knows it — rather than simply having instrumental or operational control over it.” The two books also overlap in insights — and sometimes even in language. The reader who has learned in The Intelligibility of Nature that Buffon’s method of classifying animals “reflected his belief in the importance of the senses and empiricism in learning about nature (a doctrine associated with Newton and the philosopher John Locke)” will experience a sense of déjà vu on reading, in The World as We Know It, that the classification “reflects Buffon’s commitment to the epistemological stance of Newton and his philosophical underlaborer John Locke, who stressed the role of the senses in creating natural knowledge.” Later in the passage, we read that, “because of its stress on understanding the ways of life of animals in their environments, Buffon’s approach could almost be labeled (anachronistically) as ‘ecological.’” And again, “an anachronistic way of putting it would be to say that Buffon recommends an ecological mode of understanding.” Likewise, in The Intelligibility of Nature we read of Dalton that he was initially drawn to meteorology, and that: He did a bit of experimental work on these things, especially having to do with the water-holding capacity of gases, but his real interest lay in understanding what, at an underlying natural-philosophical level, was really going on physically.” Whereas, in The World as We Know It: He did experimental work on these things, especially concerning the water-holding capacity of gases — although not at a very refined level quantitatively — but he was continually trying to develop a theoretical conception of what was happening physically. The final full chapter of each book closes on the same resigned note. Intelligibility: These days, most serious work on the natural philosophical underpinnings and implications of quantum mechanics is performed not by physicists but by philosophers of science. Among scientific practitioners themselves, Bohr’s attempt to use instrumentality as sufficient grounds for a respectable science has met with a high degree of success. And again, in The World as We Know It: Bohr’s and Einstein’s concerns are now questions that are mostly discussed by philosophers of science rather than by physicists themselves. The marginalization of these sorts of questions amounts to the demise of natural philosophy, at least in physics, in the 20th century. Quantum mechanics “works,” and that’s good enough for most scientists who encounter it. Examples could be multiplied. When handling the same subject matter, some echoes are inevitable. Scholars should not feel that because they have written “Isaac Newton died in 1727” in one book, in the next they must describe him as perishing, expiring, or meeting his maker. But the repetitions of language and arguments (not to mention six reproduced images) threaded throughout The World as We Know It are more extensive than that. They should have been caught by Princeton University Press or its reviewers, and revised. Because the two books have so much in common, it is easy to see where they diverge. The World as We Know It is a less theoretical work than its predecessor. The sociology of knowledge that organized The Intelligibility of Nature has been reduced in scale and folded into readings and examples. The taut interplay between history and theory, which gave the earlier study so much interest, is there, but it is subtle. In the earlier book, the case studies demonstrated theoretical claims about the character and development of science. In the later work, each narrative of discovery is an end in itself. Insights emerge from the history, but they do not control the organization of the study. With the theory muted, it can be hard to understand the logic uniting Dear’s sprawling history of more than two centuries of scientific knowledge. The 16 brisk chapters cover an enormous amount of material. But the closer the volume edges to comprehensiveness, the more obvious the missing elements become. A chapter on “Institutions and Pedagogy,” describing the birth of the research university, illustrates the problem. Inserted roughly halfway through the book, the unnumbered chapter is designed as an “entr’acte,” in acknowledgement that it does not fit the study’s organization around scientific discoveries. Yet as Dear is well aware, no general history of the development of modern science can bracket its 19th-century institutionalization and professionalization. It was the 19th-century university, after all, that gave us the “scientist,” a term coined by the Cambridge philosopher William Whewell. Dear’s history of scientific discoveries implies a wider social and institutional history, but it remains largely subterranean, only occasionally extruded under the pressure of the narrative. It must be said that the balance is not all on the side of the earlier study. There are some advantages to the more historical, less theoretical organization of The World as We Know It. Dear’s accounts of paradigm shifts are remarkably lucid, no small accomplishment given that they span fields and centuries. He makes excellent use of the wealth of new scholarship on Darwin and his influences, to which he has himself contributed. It is satisfying to see puzzle pieces from Buffon’s natural history, Georges Cuvier’s animal taxonomy, Thomas Robert Malthus’s demography, and Charles Lyell’s geology recombined seamlessly in the Darwinian jigsaw. Likewise, Dear’s discussion of stellar nebulae, divided between chapters two and 15, shows vividly how Newton, Kant, Herschel, and Hubble reimagined insights and observations as they sought to discover whether the diffuse light that filtered through early telescopes was a glowing, gaseous substance or discrete but distant stars. Yet despite such pleasures, the book remains a more modest work than The Intelligibility of Nature. Dear has clearly not changed his views about the history of science. But in the two decades that have elapsed, the discipline and the world around it have changed, making it harder to write a sociologically and philosophically ambitious history of science for the general reader. That is a shame, because in the age of Silicon Valley and biotechnology, both the reciprocity and the tensions Dear identified between the epistemological and instrumental ambitions of science are more evident than ever. In recent years, some of the most exciting new books on the history of science in early modernity have focused precisely on this pressure point. Important studies such as Pamela H. Smith’s From Lived Experience to the Written Word (2022), James Poskett’s Horizons: The Global Origins of Modern Science (2022), and Vera Keller’s The Interlopers: Early Stuart Projects and the Undisciplining of Knowledge (2023) all shed new light on how early modern science negotiated the relationship between its instrumental and epistemological ambitions, or in Russell’s phrase, knowing and doing. There is every opportunity for a philosophically informed approach to draw new insights from this wealth of material. Dear, unfortunately, has not done so in The World as We Know It. But for future scholars of the history of science, his body of work over nearly four decades may provide just the model. Julianne Werlin is an associate professor of English at Duke University. Thanks for reading The Chronicle Review! Subscribe for free to receive new posts and support my work. Subscribe
Anixa Biosciences Appoints UPenn's Dr. Carmen Guerra to Cancer Business Advisory Board
/PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer,...
TikTok CEO Sees AI Breakthroughs in 3 Years [2026]
TikTok CEO Shou Zi Chew says AI could drive major physics and biotech breakthroughs within two to three years, per CNBC.
China biotech RiboX reveals first data of circular RNA therapies in people
RiboX Therapeutics published first circular RNA clinical data in NEJM, showing RXRG001 improved saliva in xerostomia patients, ahead of Orna, Orbital, and Sail Biomedicines.
Europe takes cancer science into immunology
Inspired by technology and insights gleaned from cancer research, Europe is leading the quest for a new generation of therapies in immunology and inflammation. Immunotherapy has revolutionised cancer therapy and become standard of care in many areas of oncology but it has also begun to change outcomes in inflammatory and autoimmune diseases.
The longevity boom is getting ahead of the science
Billions are pouring into anti-ageing biotech, but manipulating ageing has risks we are only beginning to understand.
Anixa Biosciences Appoints UPenn's Dr. Carmen Guerra to Cancer Business Advisory Board
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced the appointment of Carmen Guerra, M.D., M.S.C.E., F.A.C.P., to its Cancer Business Advisory Board.
Future African Scientist, Two Years On: From Training Scientists to Building Africa's Biotech Companies
Martin Lubowa and Daniel Zhang on how Future African Scientist grew from a research bootcamp into the FAS Biocamp, a program turning Africa’s scientists into founders of real biotech companies. Two years ago, the Ragon had the opportunity to speak with two alumni of MIT’s Evolution of an Epidemic course, Martin Lubowa and Daniel Zhang. […]
OpenAI acquired biotech startup Orchestra Bio to expand its life sciences AI tools
OpenAI will fold Orchestra's team and technology into Rosalind, its AI models and tools for life sciences researchers
Daldrop Opens for Business in Southern Oswego County
$10 Million Facility in the L. Michael Treadwell Oswego County Industrial Park marks the largest expansion outside of Germany in the company’s 73-year history By Stefan Yablonski [caption id=attachment_11076 align=alignright width=450] Daldrop SBB CEO Jens Daldrop addresses attendees at the 2025 groundbreaking for the project. Daldrop also chairs the advisory board of Germany-based Daldrop Group.[/caption] A new era of cleanroom technology is underway in Central New York. The Daldrop Group’s advanced manufacturing facility and U.S. headquarters is physically built within the L. Michael Treadwell Oswego County Industrial Park. This industrial park is located in the town of Schroeppel. It marks the largest expansion outside of Germany in the company’s 73-year history. Daldrop SBB is based in Neckartailfingen, Germany. It is a global supplier of cleanroom technology, primarily to the pharmaceutical industry. It designs and builds advanced cleanroom environments for the pharmaceutical, biotechnology and medical technology industries. It nvested $10 million in the new project. “We broke ground in 2025; we were under construction all winter. We just opened this spring, early spring,” said Benjamin Morrow, operations manager and control. The company consolidated sites in Salina and DeWitt into the industrial park in Schroeppel, Morrow added. “The next move here is to maximize every square inch of this facility and then we are already looking at the expansion. So, it is more capital investment on equipment — definitely higher-end automation in additional equipment so we can produce more components and then to support the ever-growing base in North America,” Morrow continued. “We are the headquarters for service, maintenance and spare parts. So as Daldrop has more and more installations, they need more and more service, maintenance and spare parts. So that will come out of this facility as well — it already is.” “As a global leader in GMP (global manufacturing support) pharmaceutical cleanrooms for decades, I am very proud to bring manufacturing jobs to Upstate New York,” said Mike Sullivan, president of Daldrop US operations. Key to choosing Southern Oswego County [caption id=attachment_11077 align=alignright width=450] Daldrop SBB at the L. Michael Treadwell Oswego County Industrial Park when the company announced the start of construction.[/caption] Sullivan said that the selection of the Schroeppel industrial park was mainly due to the help of Operation Oswego County and two people in the organization. “Prior to being purchased by Daldrop International from the Stuttgart region of Germany, Vince Bongio was a founding partner in SBB Inc. as well as our head of engineering. We based out of Syracuse due to Vince’s skills in HVAC and the manufacturing capabilities found in Syracuse,” said Sullivan. Bongio moved to Syracuse from California in the 1970s to work in Carrier’s Industrial Division of Large-Scale Petrochemical Refrigeration. Next, he advanced to General Electric’s TV Tube Plant where he got into cleanrooms ,leading to his role of head of engineering for Clestra Cleanrooms where he met Sullivan, their New England distributor. “Vince Bongio is a phenomenal engineer. Formerly of Carrier, he grew up in California and went to Cal Poly,” Sullivan explained. “Carrier hired him right out of college and he moved to Syracuse. He is the reason we are in Syracuse today. He is retiring this year. We are very proud and his legacy is having brought Daldrop to Syracuse.” In 2000, Sullivan, Bazinet, Bongio Inc (SBB) was formed with engineering and manufacturing, based in Syracuse, and sales and construction based in Massachusetts as it is today. “SBB Inc. started in Syracuse. I had a design–build contracting firm out of Massachusetts that was primarily doing all the new technologies coming out of MIT,” Sullivan said. “I started a manufacturing side. A big thing for cleanrooms is the HVAC. Most cleanroom suppliers are architecturally focused people. The strength in Syracuse is HVAC. So, SBB developed with me running sales and construction out of Massachusetts and manufacturing out of Syracuse.” “Daldrop wanted to have a relationship in the States and of those who approached us, they were the only ones who really understood HVAC. So, we were the right fit for them. We did a joint venture focused out of Massachusetts from 2012 to 2018 leveraging their technologies,” Sullivan explained. “The commitment was if we brought their product to the States, we would do that if they built it here. “The pieces that had to be in place to make the investment, they wanted to acquire us, we were great with that. If you looked at business recommendations the general guidance was to build in a low labor area — something like North Carolina — but Syracuse had a strong background in HVAC and we chose Syracuse and Oswego County to be our headquarters in the States. So, it is built off of history, technology and the existing supply chain — bringing jobs back to the area.” During the initial discussions with Daldrop about coming to the U.S., SBB agreed to sell under the conditions Daldrop would manufacture in the U.S. There are many areas that offer incentives and economic packages, but the strength of HVAC expertise and skilled manufacturing was a big part of the discussions for site selection. Coming home [caption id=attachment_11078 align=alignright width=451] Construction moves forward in March at the L. Michael Treadwell Oswego County Industrial Park.[/caption] The second key person to building in Oswego County is Ben Morrow, Sullivan added. “Ben has been working with Daldrop SBB for more than 12 years and has advanced to COO of manufacturing and engineering. Ben grew up in Phoenix, so building a factory for the Germany company in Phoenix is a strong success for both his community and the appreciation of Ben’s skills as a team leader,” Sullivan said. “I went to high school in Phoenix. So, this is like full circle for me. It’s a small world,” Morrow said. “I hadn’t been back to Phoenix since graduation. This is one of the properties that John Trimble of C&S, he is the former president of C&S, he just retired, suggested. He and I were very good personal friends. John was from Mexico and I was from Phoenix. We knew each other from high school. And the architect of this building, Ed Smart of smartDESIGN Architecture in Batavia — I went to high school with him. So, this was a project that’s full circle a coming home kind of thing. The three of us knew each other — kind of like it was meant to be. Very serendipitous.” Schroeppel was one option for Daldrop to consider; the original intent was just to get a warehouse to store some product, he added. The facility is Daldrop’s largest outside of their native country. Total payroll at the facility will be approximately $2.4 million once fully staffed. “Here is 32,000 square feet and we plan to expand and put in an additional 10,000 square feet,” Morrow said. “We have 17.5 acres. We can put at least three more facilities here, just on this property. The master plan submitted for the current building is the first of possible three buildings on the campus.” “If we can find the right people and advance the production according to the plan, we should be able to grow for the next decade. One of the first jobs we filled was our new HR manager, with a primary focus posting and filling new positions,” Sullivan said. Stop the exodus, start hiring [caption id=attachment_11080 align=alignright width=452] Principals at the local Daldrop SBB headquarters, from left: Ben Morrow, Mike Sullivan and Jens Daldrop.[/caption] “I have been coming to Syracuse for 30 years. One of the things I had a hard time watching was the exodus of factories. One of the toughest things is to watch it with my partners’ kids who had to move away for jobs. It is important for us to give opportunity where people’s kids don’t have to leave the area to get work,” Sullivan said. “My responsibility is to find people who have skill sets that want to work and then I have to build opportunity for that work to happen. “After years of watching companies and Vince’s three sons all move out of the areas to get jobs, it is important to us to provide opportunities for the Syracuse region and help grow our company. We have been hiring for our new factory and will continue for the next few years.” “We are hiring and will continue to hire. Currently we have about 19 on staff right now,” Morrow said. “We expect to grow that by about 10 to 15 in the next 12 to 18 months or so. We are at 19 currently — one in the wings. It’s been great being able to hire locally. All these folks that we’ve been hiring, they all live within a few miles from here.” “We hired someone this past week (end of August). She grew up in the area, raised a family and is working down in Florida. She just took a job with us so she can move back and be with her family. We will be moving her back and she should be starting in October. We are very happy to see this happen,” Sullivan said. “I feel strongly about having a spot for the kids to not have to move out of the area. It is better to have people moving into the area.” Currently, Daldrop SBB has openings for finance manager, COO of construction and delivery, as well as mechanical, electrical designers and Revit modelers, construction managers, commissioning agents and many other skills that are needed. Along with Daldrop’s reputation in life science cleanrooms, there is a strong history in semiconductor, electronics, glass, photonics, aerospace and other markets. This may be helpful with any new technologies building in the market such as the Micron expansion and the support network, Sullivan said. “We acquired this property and closed on it two months before any announcement from Micron. It is serendipitous that they’re right down the street from us,” Morrow added. “Everybody started thinking ‘you guys are supporting Micron.’ We were here first. That is not a goal of ours. We may or may not … they are talking to us; it is an opportunity.” The long run [caption id=attachment_11079 align=alignright width=450] Benjamin Morrow, operations manager and control at Daldlrop, speaks during a recent ribbon-cutting event in Schroeppel.[/caption] “Long term, we will expand the Phoenix facility,” Sullivan said. “We built our facility with a campus approach. Sustainability is big. We designed our rooms to be more sustainable. Our building has no gas lines for heat. We put geothermal wells in the ground. We put heat pumps in for heating and cooling out of those wells and we put a large layer of solar panels up on the roof. We worked with National Grid for metering. Our building is a high efficiency model. We upgraded all the instillation and the glass filtering. So, it is a very green building. We will have a very minimal carbon footprint. It also adheres to LEED (Leadership in Energy and Environmental Design) construction standards.” “We are a bunch of HVAC engineers. We did a large scale geothermal and spent the money up front because we knew it made sense in the business sense in the environmental sense and sustainability,” Morrow said. “We have insulated metal panels on walls and roof; we are an envelope from the exterior.” Daldrop, as a global player, has a strong culture of sustainability that is found in all its products including the new facility. The building has been designed with (sixteen) 400-foot deep geothermal wells, high efficiency construction methods, approximately 70 kilowatt solar photovoltaic panels, electric vehicle chargers and 26% recycled content. “Daldrop thinks of long-term investing,” Sullivan said. “On the roof, photovoltaic panels supplement our power. Over half the energy that I use is coming from the sun. We have chargers up front for employee electric vehicles. This place is built to last. This slab that we are walking on, normal buildings are four inches, some go to six inches, we are nine inches all the way through — except where the heavy equipment is — that is 10 to 12 inches thick, solid concrete. It allows us to reconfigure for whatever type of equipment we want to bring in,” Morrow said. “We are authorized by Underwriters Laboratory to self-certify so we don’t need to have an inspector come out and recertify. We get audited often, but we certify our own electronics. The control system in this building is rather high-end. Our thermostat in every room is zoned, independent. We analyze the data; incorporate it with our solar panels.” “There is a lot of competition for people to work. It’s not just about how much salary they are going to make — it’s about the work environment, the ability for stability. We want to make sure our employees have the best environment to work in,” Morrow added. Similarities “One of the reasons I believe why Daldrop chose this area, Phoenix in particular, is because it is a village, a river-based village. Neckartailfingen in Germany where Daldrop is based is also a river-based village, manufacturing community. So, there is a lot of similarities — that smalltown feel,” Morrow said. “We have a lot of connections through multiple employees that lead back to Carrier, also. Everything came together, the timing everything.” “We are thankful for all the economic development support. Everyone has been helping make this happen. So, keep it up, it is working, that is all I got to say, Sullivan said. “If you look at historical industrial manufacturing, this region has skills that have been un-utilized. The northern industrial region has a lot of skills that if we can tap before they go away, we can leverage them. That is what we are trying to do. You’d be surprised at the supply chain left behind from Carrier — that supply chain is still there.” “Operation Oswego County has been fantastic,” Morrow added. “I can’t say enough good things about that group.” What Is Cleanroom Technology Cleanroom technology is a system of specialized engineering, filtration and operational controls used to maintain an extremely low concentration of airborne particles, microbes and chemical vapors. How It Works • Air Filtration: Uses HEPA or ULPA filters to remove 99.97% of tiny particles down to 0.3 microns. • Airflow Control: Directs air in a steady, unidirectional (laminar) or filtered turbulent pattern to push dust away from work areas. • Environmental Regulation: Maintains precise control over temperature, humidity and positive air pressure to block outside air leaks. • Specialized Attire: Requires personnel to wear full-body garments (“bunny suits”), gloves and masks to stop human shedding
I run a cancer biotech company. Then, I was diagnosed with cancer.
Dr. Ryan Beal is the CEO of Dyve, a cancer-biotech company. He, his dad, and his mom have all had cancer.
MRM Health and Biocodex establish strategic partnership to strengthen future commercial supply capabilities for CORAL®-based medicines
MRM Health, a clinical-stage biotech developing microbiome-based therapies for immune-mediated diseases, and Biocodex, an independent French pharmaceutical company with more than 70 years of experience in the microbiome field, today announced the launch of a strategic partnership to establish specialized manufacturing capabilities for live biotherapeutic products.
Axios Live: Research and manufacturing investments boost Philadelphia's biotech role
Significant investments in biotech research and manufacturing are positioning the Philadelphia region for new jobs and broader economic growth
Vir Biotechnology appoints Suzanne Topalian to board and Science and Technology Committee
Vir Biotechnology appointed Suzanne Topalian, M.D., to its board and Science and Technology Committee, effective October 27, 2026.Original SEC Filing: Vir Biotechnology, Inc. [ VIR ] - 8-K - Oct. 28, 2026This is an AI-powered summary. It may contain inaccuracies. Consider verifying important inform…
Why we’re still so obsessed with Elizabeth Holmes
You Can See Everything, a documentary about the disgraced biotech company founder Elizabeth Holmes, has enjoyed a record-breaking opening in the US. It is a testament to how fascinated we remain by the convicted fraudster, but what is behind the enduring appeal? US technology editor Blake Montgomery tells Madeleine Finlay why Holmes continues to fascinate us, and reflects on whether the Theranos scandal has had a permanent impact on Silicon Valley
Business and medicine cross paths at inaugural cancer innovation summit
During a sold-out summit that spanned Monday and Tuesday, statewide nonprofit BioCT and the Yale Cancer Center connected hundreds of attendees with over 70 speakers, who presented on recent developments in cancer treatment and biotechnology.
Rome hosted second India-Italy Science & Innovation Dialogue
India and Italy strengthened their technology partnership during the Second India-Italy Science & Innovation Dialogue in Rome. The dialogue focused on advancing joint priorities in advanced sciences, digital transformation, and industrial research, emphasizing translational research and multisectoral cooperation in fields like AI, clean energy, and biotech. The discussions laid the groundwork for future joint research calls and strengthened institutional partnerships
‘Political manipulation’: Trump admin alleges Chinese ‘biotech companies of concerns’ use ‘forced labor’ to source materials, barring imports
The latest trade actions precede an expected meeting next month between Chinese leader Xi Jinping and U.S. President Donald Trump.
Bon Secours Mercy Health to acquire majority stake in Surgery Partners in $5.7B deal
Bon Secours Mercy Health is acquiring a majority share in healthcare services company Surgery Partners in a take-private deal valuing the acquiree at $5.7 billion, the organizations announced Monda | The pending deal values the short-stay surgical platform at $5.7 billion, and is the latest example of large health systems' push to build out their ambulatory networks.
Medicus Pharma proposes $135M SkinJect spinout through SPAC business combination
Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive to discuss a proposed transaction involving the company's wholly owned subsidiary, SkinJect, which has entered into a non-binding letter of intent with an undisclosed special purpose acquisition company (SPAC) for a potential business combination. The proposed transaction contemplates a US$135 million pre-money enterprise valuation for SkinJect, alongside a concurrent equity financing intended to support the company's SKNJCT-005 clinical study in patients with Gorlin syndrome and preparations for a potential New Drug Application (NDA). Bokhari told Proactive that the proposed deal is designed to establish SkinJect as a separately listed company focused on advancing its dermatology and rare-disease development program. Under the proposed structure, the SPAC would acquire 100% of SkinJect in exchange for newly issued common shares in the combined company. Medicus Pharma intends to retain majority economic and voting ownership, allowing existing Medicus shareholders to maintain significant participation in SkinJect's potential future value. The separation would also provide SkinJect with a dedicated financing platform to fund its clinical development activities, particularly the SKNJCT-005 study targeting Gorlin syndrome, a rare genetic condition associated with the development of multiple basal cell carcinomas. The concurrent financing is expected to support the clinical program and the work required to prepare and potentially submit a New Drug Application, subject to successful development and regulatory progress. Final ownership percentages have not yet been determined. These will depend on negotiations surrounding the definitive transaction agreement and the combined company's capitalization, including retained SPAC cash, public and sponsor shares, warrants and other potentially dilutive securities. Medicus said the proposed transaction remains subject to the completion of definitive documentation and other customary conditions. The planned spinout represents a strategic step in Medicus Pharma's efforts to give SkinJect a dedicated corporate and financial structure, while allowing the parent company to retain majority participation as the dermatology program advances towards its next clinical and regulatory milestones. #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #SkinJect #Biotechnology #Healthcare #RareDisease #GorlinSyndrome #Dermatology #SPAC #ClinicalTrials #DrugDevelopment #NDA #Biopharmaceuticals
life – the bioRN Life Science Cluster magazine
Alliances for success – Heidelberg and the Rhine-Neckar region are among the most dynamic life science ecosystems in Europe.
GenScript Launches Life Sciences Startup PitchFest with NVIDIA to Accelerate Biotech Innovation
/PRNewswire/ -- GenScript Biotech Corporation today announced the GenScript and NVIDIA Life Sciences Startup PitchFest, a global competition for startups...
Chinese scientists fired after child dies in gene editing study: report
Chinese authorities have fired two researchers over their roles in the death of a child in a gene editing study, according to a report in Chinese state media. The researchers were dismissed and barred from government science projects for five years, China Central Television (CCTV) reported Nov. 13. Authorities took the actions after finding the researchers failed to promptly report a preclinical safety signal, emphasize the risk of death in the informed consent form or disclose the death in a journal paper, according to CCTV. The probe also found fault with the ethics review process. Other findings included undisclosed conflicts of interest. Families gave the researchers money and gifts totaling about 1.1 million Chinese yuan ($160,000). The gifts, which were not disclosed in the research paper, included high-end liquor and electronic products, CCTV reported. The findings triggered the dismissal of the person in charge of preclinical research and a key member of their team. Five other people received punishments ranging from demotions to administrative warnings, according to CCTV. Authorities outlined actions they are taking to improve practices. Multiple organizations must submit written self-examinations and take steps to rectify the failings identified in the investigation, CCTV said. Authorities plan to strengthen oversight of clinical trials involving new biomedical technologies, such as gene editing therapies, according to the article. The actions come as China implements new rules on investigator-initiated trials (IITs), which have enabled drug candidates to move quickly into early clinical development but raised questions about the adequacy of oversight and safety reporting. The revised rules limit which sites can run IITs and impose additional requirements on the studies. China implemented the new rules in May. Science and Retraction Watch reported the child’s death in July, triggering the investigation that led to the dismissals and other penalties. The child received a gene therapy to correct a genetic mutation that impaired brain development. In August, Stat uncovered that a young boy enrolled in HuidaGene Therapeutics’ IIT trial for Duchenne muscular dystrophy died last year of acute respiratory distress syndrome following administration of a CRISPR-based treatment. Together, the two incidents—both involving severe immune reactions to high-dose, viral vector-delivered gene therapies and a lack of disclosure—drew international scrutiny to what appeared to be systemic gaps in oversight and transparency within China’s IIT framework.
How Biotechnology Could Protect the Crops We Depend On
Crop biotechnology could protect vital food crops from disease, pests and climate stress, with bananas showing the potential of modern tools.
MitoRx Therapeutics Appoints Neil Anderson as Chief Business Officer
Neil joins from Novo Nordisk and brings more than 20 years of experience in business development and strategic transactionsAppointment strengthens MitoRx’s business development capabilities as the Company advances MTRX31 towards the clinic for metabolically unhealthy obesity Harwell Oxford, UK – 3 November 2026: MitoRx Therapeutics (“MitoRx”), a biotech company targeting the restoration of healthy mitochondrial metabolism in high-risk obesity, today announces the appointment of Neil Anderson, Ph
How a Ms. Frizzle-esque librarian helped Flagship’s Louisa Helms find biotech
BioSpace 40 Under 40 honoree Louisa Helms is a lot of things—athlete, scientist, entrepreneur and likely future biotech executive. Just don’t ask her to pick up any pipettes.
Endpoints seeks a business of science reporter
Endpoints News is hiring a biotech journalist to cover how advanced therapies and drug technologies turn into the medical products of tomorrow. The right candidate is business-savvy and science-minded. In this job, you’ll write about clinical trials, startups and the business of science. You’ll be responsible for helping set the agenda on a busy beat […]
Campbell hosts Harnett business leaders for economic update
Photo by Campbell University Harnett County has grown more than 27% over the last 15 years and is on the cusp of significant growth in the business sector as well. Campbell University recently hosted the 2026 Harnett County Economic Development Update; this was the university's third year in a row hosting the event. The annual event invites elected officials, business leaders and stakeholders from Harnett and its neighboring counties to share updates on new projects, economic trends and announcements from the previous year. Campbell’s continued involvement is part of its five-year Strategic Plan, launched earlier this year, which lists “community impact” as one of its four main objectives. “Every place I have ever worked, the university has been viewed by its surrounding community and region as an asset to economic development, as an inducement to business and industry and as a driver of innovation. It has been seen as the indispensable partner for growth,” Campbell President Dr. William M. Downs told the group of about 200 in attendance. “We ask that you save us a seat at your table when you are dreaming big about the future of this county and beyond. Campbell University is open for business, and we’d like to do business with you.”In addition to Campbell, Harnett is home to Harnett County Schools and its Career & Technical Education programs and a satellite campus of Central Carolina Community College, home of the Eugene Moore Manufacturing & Biotech Solutions Center (the largest training facility in the state). Stephen Barrington, Harnett County Economic Development director, shared the county’s latest initiatives, focus areas and opportunities in economic development. He lauded Campbell and the county’s strong educational and training infrastructure for training the area’s current and future workforce.“Workforce is at the top of the list when we talk about economic development,” Barrington said in a press release. “Work and skill-ready talent remains at the top of the list [of assets in Harnett County]. We’re extremely grateful for the education and training of our students for the next generation.”One big project landed in September when Harnett County was awarded a $500,000 Build Ready Sites grant from the North Carolina Railroad Company to advance a rail-served industrial site. The investment will help prepare the property for future development and strengthen Harnett County’s ability to compete for rail-served projects. The funding will support Byrd Industrial Site B, an 83-acre site with 58 developable acres within the Byrd Industrial Sites in Lillington.Harnett County is also actively working with Samet Corp. is actively working with Samet Corp. on the development of a 175,500-square-foot speculative industrial building to stimulate economic development.Featured speaker was Ted Abernathy, founding and managing partner of Economic Leadership, a small group of data, strategy and best-practice policy experts that work with companies, foundations and business organizations to analyze competitiveness, develop strategy, support leadership, tune communications and reimagine the future.Abernathy lauded Harnett County’s proximity to one of the fastest-growing and most business-friendly regions in the country — the Research Triangle and Raleigh-Durham metropolitan area — and said Harnett needs to attract more businesses that offer higher-paying jobs to compete. “The quality of the jobs you attract is one of the challenges for you as you go forward,” Abernathy said in a press release. “You need more high-paying jobs. A big chunk of the population here is making $25 to $50 an hour, which is good. But where you’re really weak is this high end. If you looked at Raleigh or Durham or Mecklenburg, that number would be a third of their jobs.”Learn more about Harnett County Economic Development and current projects happening at harnettedc.org.
Dealroom.co | RegCell raises $44M Series A to move Nobel-winning Treg science to the clinic
What's the deal? RegCell, an Emeryville, California biotech co-f…
All Roads Lead to Texas: 15th Annual Texas Life Science Forum to Bring Together Biotech’s Builders and Backers on Nov. 10 in Houston
The Rice Alliance for Technology and Entrepreneurship and BioHouston today announced that the 15th Annual Texas Life Science Forum is set for Tuesday, Nov. 1...
Geneva Health Forum 2026: Rethinking cooperation in global health
From November 10 to 12, at the Biotech Campus in Geneva, the Geneva Health Forum (GHF) will bring together healthcare professionals, researchers, institutional leaders, and representatives from international and humanitarian organizations for three days of debate, networking, and the sharing of experiences.
‘The Maine Question’ podcast explores how Maine can expand its healthcare industry
Maine’s working waterfront has long been dominated by fishermen, shipbuilders and other heritage industries, but a growing number of commercial aquaculture farms, charter and tour boat operators, biotechnology firms, research institutes, restaurants and gift shops have joined these heritage enterprises along the coast. Driven by new markets and technology, Maine…
Not All Magnesium Supplements Are Equal: What Science Says About Absorption
Magnesium has quietly become one of the most talked-about minerals in nutrition science, and a new narrative review published in Food Science and Biotechnology by Sanem Gultekin and Merve Tomas of Istanbul Technical University explains why the supplement aisle may be far more